Skip to main content

Table 1 Characteristics of the study patient population at the time of CMV-TCIP

From: Clinical experience with a novel assay measuring cytomegalovirus (CMV)-specific CD4+ and CD8+ T-cell immunity by flow cytometry and intracellular cytokine staining to predict clinically significant CMV events

Parameter Patients
(N = 37)
CMV events
(N = 16)
No CMV events
(N = 28)
Age (years) (mean ± SD) 56.4 ± 15.4 51.5 ± 17.7 57.9 ± 13.6
Women (%) 15 (40.5) 9 (56.3) 12 (42.8)
SOT (%) 31 (83.7) 15 (93.7) 23 (82.2)
 Kidney (%) 20 (54.1) 9 (56.3) 15 (53.6)
 Kidney-pancreas (%) 2 (5.4) 1 (6.3) 1 (3.5)
 Heart (%) 6 (16.2) 4 (25) 5 (17.9)
 Lung (%) 2 (5.4) 1 (6.3) 1 (3.5)
 Liver (%) 1 (2.7) 0 (0) 1 (3.5)
 High-risk for CMV (CMV D+/R-) (%) 20 (54.1) 12 (75) 14 (50)*
 Time from transplant (months) (median, IQR) 11.9 (7.1–17.2) 10.2 (8.3–18.5) 12 (7–16.7)
Induction immunosuppression
 Thymoglobulin (%) 6 (16.2) 4 (25) 5 (17.9)
 Alemtuzumab (%) 6 (16.2) 2 (12.5) 4 (14.2)
 Basiliximab (%) 16 (43.2) 8 (50) 11 (39.3)
 None (%) 1 (2.7) 0 (0) 1 (3.5)
 Unknown (%) 2 (5.4) 1 (6.3) 2 (7.1)
Maintenance immunosuppression
 2 agents (%) 12 (32.4) 6 (37.5) 9 (32.1)
 3 agents (%) 19 (51.3) 9 (56.3) 14 (50)
 High-dose mycophenolate (%)a 5 (13.5) 2 (12.5) 4 (14.2)
 Tacrolimus trough level (ng/dL) (mean ± SD) 8.2 ± 4.2 8.6 ± 4.9 7.9 ± 3.8
 Prednisone > 5 mg daily (%) 15 (40.5) 4 (25) 13 (46.4)
Non-SOT (%) 6 (16.2) 1 (6.3) 5 (17.8)
ALC (109/Lt) (mean ± SD) 1 ± 0.79 1 ± 0.88 1 ± 0.76
  1. Data are presented as absolute number (% within column) for categorical variables and mean ± standard deviation (SD) or median (interquartile range, IQR) for continuous variables with a normal or non-normal distribution, respectively
  2. ALC Absolute lymphocyte count, CMV D+/R- Donor positive-recipient negative CMV seropositivity status, SOT Solid organ transplant
  3. *P = 0.1
  4. aMycophenolic acid 720 mg or mycophenolate mofetil 1 g twice daily